Skip to main content

Table 2 Observed incidence of GBS per 100,000 person-years for 2009–2011 in the population of 4.68 million under surveillance by the neurologist network

From: Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

  Male Female Total
Age group in years Cases Person-years Incidence 95 % CI Cases Person-years Incidence 95 % CI Cases Person-years Incidence 95 % CI
20–29 6 1,232,652 0.49 (0.18–1.06) 5 1,224,264 0.41 (0.13–0.95) 11 2,456,916 0.45 (0.22–0.80)
30–39 12 1,607,871 0.75 (0.39–1.30) 11 1,560,600 0.70 (0.35–1.26) 23 3,168,471 0.73 (0.46–1.09)
40–49 14 1,350,147 1.04 (0.57–1.74) 7 1,354,077 0.52 (0.21–1.07) 21 2,704,224 0.78 (0.48–1.19)
50–59 10 991,665 1.01 (0.48–1.85) 15 1,045,449 1.43 (0.80–2.37) 25 2,037,114 1.23 (0.79–1.81)
60–69 17 783,156 2.17 (1.26–3.48) 7 845,904 0.83 (0.33–1.71) 24 1,629,060 1.47 (0.94–2.19)
70–79 14 569,067 2.46 (1.34–4.13) 12 712,188 1.68 (0.87–2.94) 26 1,281,255 2.03 (1.33–2.97)
80+ 9 272,355 3.30 (1.51–6.27) 2 503,019 0.40 (0.05–1.44) 11 775,374 1.42 (0.71–2.54)
Total ≥20 years 82 6,806,913 1.20 (0.96–1.50) 59 7,245,501 0.81 (0.62–1.05) 141 14,052,414 1.00 (0.84–1.18)
  1. GBS indicates Guillain-Barré syndrome, CI confidence interval